Acrivon Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 60.39 million compared to USD 31.17 million a year ago. Basic loss per share from continuing operations was USD 2.74 compared to USD 7.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 USD | -1.23% | -6.09% | +47.36% |
05-14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.36% | 224M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- ACRV Stock
- News Acrivon Therapeutics, Inc.
- Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023